Rhesus macaque VEGF R1 / Flt-1 Protein, Mouse IgG2a Fc Tag, low endotoxin
VE1-R5257
1mg
Brand
ACROBiosystems
Description
Source :
Rhesus macaque VEGF R1, Mouse IgG2a Fc Tag, low endotoxin (VE1-R5257) is expressed from human 293 cells (HEK293). It contains AA Ser 27 – Asn 756 (Accession # F7FAY2-1).
Molecule : VEGF R1
Synonyms : FLT,VEGFR1,FLT1
Format : Powder
Category : Bio-Markers & CD Antigens
Accession : XP_001117928.2
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 109.1 kDa
Characteristics :
This protein carries a mouse IgG2a Fc tag at the C-terminus. The protein has a calculated MW of 109.1 kDa. The protein migrates as 130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level : Less than 0.1 EU per μg by the LAL method.
Buffer : Tris with Glycine, Arginine and NaCl, pH7.5
Description :
Vascular endothelial growth factor receptor 1 (VEGFR1) is also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.
References :
(1) Shibuya M., et al., 1990, Oncogene 5:519-524.
(2) Kendall R.L., et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10705-10709.
(3) Seetharam L., et al., 1995, Oncogene 10:135-147.
(4) Barleon B., et al., 1996, Blood 87:3336-3343.
(5) Grunewald F.S., et al., 2010, Biochim. Biophys. Acta 1804:567-580.
(6) Iyer S., et al., 2010, J. Biol. Chem. 285:23779-23789.
Application
Reactivity